SEARCH

SEARCH BY CITATION

References

  • 1
    Garcia-Tsao G, Sanyal AJ, Grace ND, Carey W. Prevention and management of gastroesophageal varices and variceal hemorrhage in cirrhosis. Hepatology 2007; 46: 92238.
  • 2
    Qureshi W, Adler DG, Davila R, et al.ASGE guideline: the role of endoscopy in the management of variceal hemorrhage, updated July 2005. Gastrointest Endosc 2005; 62: 6515.
  • 3
    Jalan R, Hayes PC. UK guidelines on the management of variceal haemorrhage in cirrhotic patients. British Society of Gastroenterology. Gut 2000; 46: III115.
  • 4
    Albillos A, Rossi I, Iborra J, et al.Octreotide prevents postprandial splanchnic hyperemia in patients with portal hypertension. J Hepatol 1994; 21: 8894.
  • 5
    McCormick PA, Biagini MR, Dick R, et al. Octreotide inhibits the meal-induced increases in the portal venous pressure of cirrhotic patients with portal hypertension: a double-blind, placebo-controlled study. Hepatology 1992; 16: 11806.
  • 6
    Jenkins SA, Baxter JN, Critchley M, et al. Randomised trial of octreotide for long term management of cirrhosis after variceal haemorrhage. BMJ 1997; 315: 133841.
  • 7
    Spahr L, Giostra E, Frossard JL, Morard I, Mentha G, Hadengue A. A 3-month course of long-acting repeatable octreotide (sandostatin LAR) improves portal hypertension in patients with cirrhosis: a randomized controlled study. Am J Gastroenterol 2007; 102: 1397405.
    Direct Link:
  • 8
    Ottesen LH, Flyvbjerg A, Jakobsen P, Bendtsen F. The pharmacokinetics of octreotide in cirrhosis and in healthy man. J Hepatol 1997; 26: 101825.
  • 9
    Gillis JC, Noble S, Goa KL. Octreotide long-acting release (LAR) A review of its pharmacological properties and therapeutic use in the management of acromegaly. Drugs 1997; 53: 68199.
  • 10
    Groszmann RJ, Glickman M, Blei AT, Storer E, Conn HO. Wedged and free hepatic venous pressure measured with a balloon catheter. Gastroenterology 1979; 76: 2538.
  • 11
    Buonamico P, Sabba C, Garcia-Tsao G, et al. Octreotide blunts postprandial splanchnic hyperemia in cirrhotic patients: a double-blind randomized echo-Doppler study. Hepatology 1995; 21: 1349.
  • 12
    Sabba C, Ferraioli G, Genecin P, et al. Evaluation of postprandial hyperemia in superior mesenteric artery and portal vein in healthy and cirrhotic humans: an operator-blind echo-Doppler study. Hepatology 1991; 13: 7148.
  • 13
    Escorsell A, Bandi JC, Andreu V, et al.Desensitization to the effects of intravenous octreotide in cirrhotic patients with portal hypertension. Gastroenterology 2001; 120: 1619.
  • 14
    Baik SK, Jeong PH, Ji SW, Yoo BS, Kim SK, Lee DK, et al. Acute hemodynamic effects of octreotide and terlipressin in patients with cirrhosis: a randomized comparison. Am J Gastroenterol 2005; 100: 6315.
  • 15
    Moller S, Brinch K, Henriksen JH, et al. Effect of octreotide on systemic, central and splanchnic hemodynamics in cirrhosis. J Hepatol 1997; 26: 102633.
  • 16
    Albraldes JG, Bosch J. Sandostatin and analogues in portal hypertension. Hepatology 2002; 25: 130512.
  • 17
    Malesci A, Taccon M, Valentini A, Basilico M, Lorenzano E, Salerno F. Octreotide long-term treatment in patients with portal hypertension: persistent intubation of postprandial glucagon response without major change in renal function. J Hepatol 1997; 26: 81625.
  • 18
    Chatila R, Ferayorni L, Gupta T, Groszmann RJ. Local arterial vasoconstriction induced by octreotide in patients with cirrhosis. Hepatology 2000; 31: 5726.